Dexmedetomidine ameliorates high‐fat diet‐induced nonalcoholic fatty liver disease by targeting SCD1 in obesity mice

Fatty liver disease is one of the main hepatic complications associated with obesity. To date, there are no therapeutic drugs approved for this pathology. Insulin resistance (IR) is implicated both in pathogenesis of nonalcoholic fatty liver disease (NAFLD) and in disease progression from steatosis...

Descripción completa

Detalles Bibliográficos
Autores principales: Tao, Linfen, Guo, Xiaolong, Xu, Min, Wang, Yumeng, Xie, Wenhua, Chen, Hong, Ma, Mengyao, Li, Xi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7753983/
https://www.ncbi.nlm.nih.gov/pubmed/33474802
http://dx.doi.org/10.1002/prp2.700

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7753983/
https://www.ncbi.nlm.nih.gov/pubmed/33474802
http://dx.doi.org/10.1002/prp2.700

Ejemplares similares